Studies thus far suggest that facilitation of KCa2.X/KCa3.1 activity in vivo by a positive modulator is free from major adverse effects, but more work will be necessary to determine whether this strategy could have unwanted effects in the setting of atherosclerosis. The gene discussed is KCNN4; the disease is atherosclerosis.